Del. Chancery Lets Caremark Oversight Claims Proceed in Teligent

Every so often, Delaware corporate law hands boards and executives a case that feels less like a gentle reminder and more like a fire alarm with footnotes. Giuliano v. Grenfell-Gardner, the Teligent decision from the Delaware Court of Chancery, is that kind of case. It sits at the intersection of board oversight, FDA compliance, bankruptcy, and the famously difficult Caremark doctrine. In other words, it is catnip for governance lawyers and nightmare fuel for anyone who treats compliance as an optional side quest.

The headline is simple: Chancellor Kathaleen McCormick allowed major oversight claims to move forward against most of Teligent’s former directors and certain former officers. But the path to that result matters just as much as the result itself. This was not a routine stockholder derivative suit. It became a direct, post-bankruptcy action brought by the company’s successor through a plan administrator. That twist gave the plaintiff access to a mountain of internal company records and stripped away the usual demand-futility hurdle that often crushes Caremark cases before they leave the station.

For boards, officers, general counsel, and compliance teams, the message is hard to miss: when a company operates in a heavily regulated industry, oversight of core legal and regulatory risks cannot live in a vague cloud of assumptions, hallway conversations, or “I thought someone else had that.” Delaware still sets a high bar for oversight liability, but Teligent shows that the bar is not decorative.

What Happened in Teligent?

Teligent was a New Jersey-based generic pharmaceutical company that manufactured and sold topical creams and injectable drugs in the United States. That mattered because FDA compliance was not some nice-to-have corporate virtue badge. It was foundational to the company’s ability to make products, win and maintain approvals, and generate revenue. No FDA compliance, no smooth path to approvals. No approvals, no products. No products, no revenue. That is not subtle. That is the business model wearing a name tag.

According to the complaint the court had to accept as true at the motion-to-dismiss stage, Teligent faced escalating FDA compliance trouble from 2016 through 2021. The company’s Buena, New Jersey facility drew significant scrutiny, and the FDA’s 2019 warning letter cited serious current good manufacturing practice violations. Public filings and company statements also showed that the warning letter had material operational and financial consequences, including remediation efforts, delayed regulatory progress, and impairment issues tied to uncertainty about whether the warning letter would be lifted.

Then the corporate picture got uglier. In October 2021, Teligent filed for Chapter 11 bankruptcy, citing regulatory and legal setbacks among the causes of its distress. A bankruptcy plan administrator later caused the company’s successor to pursue the fiduciary-duty claims directly. That procedural move changed the litigation in a big way. Instead of a stockholder suing on the company’s behalf while fighting through demand rules and limited information, the company itself became the plaintiff, armed with internal emails and records. In plain English: the plaintiff got a backstage pass.

Why This Case Matters in the World of Caremark

If you have spent any time around Delaware corporate law, you have probably heard that Caremark claims are among the hardest claims in the field. That reputation is well earned. Delaware courts do not impose liability just because bad things happened, regulators got angry, or Monday morning quarterbacks can draw a cleaner org chart after the crisis. The doctrine is aimed at bad-faith failures of oversight, not simple sloppiness.

Even so, Teligent matters because it shows how oversight claims can survive when the alleged failure is tied to a company’s central compliance risks and the complaint can point to concrete gaps in board-level systems. The court emphasized that directors retain broad discretion in designing oversight structures. But discretion is not the same as disappearing. Boards must make a good-faith effort to establish a reasonable system for monitoring and reporting on important risks.

That distinction is the whole game. Delaware does not demand a perfect compliance machine wrapped in platinum-plated checklists. It does, however, expect a real effort. Teligent is notable because the alleged facts suggested not merely a weak system, but a near-vacuum where one should have been.

The Direct-Claim Twist

One of the most important features of Teligent is its posture. The court described the case as unusual because the claims were not being asserted derivatively after bankruptcy. The company’s successor, acting through the plan administrator, brought them directly. That meant the usual demand requirement did not apply. It also meant the plaintiff had broad access to books, records, and internal communications. The court openly noted that, given the plaintiff’s informational advantage compared to ordinary Caremark plaintiffs, it was no shock that the complaint stated claims against most defendants.

This matters beyond Teligent. Companies sometimes assume bankruptcy wipes the governance slate clean or at least buries old oversight failures under larger restructuring drama. Teligent suggests otherwise. Post-bankruptcy fiduciaries may inherit not just corporate assets and headaches, but also litigation theories with sharper teeth than the original stockholders could easily deploy.

Information-Systems Claims vs. Red-Flags Claims

The decision is also a useful lesson in the two familiar branches of Caremark theory. First, there are information-systems claims: allegations that the board failed to put a reasonable monitoring and reporting system in place. Second, there are red-flags claims: allegations that directors or officers saw danger signs and consciously ignored them.

In Teligent, the board-level information-systems theory survived, but the board-level red-flags theory did not. That split is one of the most interesting parts of the opinion. The court explained that the stronger the allegation that there was no real board-level reporting system, the harder it may be to infer that the board actually received clear red flags through such a system. Put differently, a board cannot knowingly ignore warnings that it plausibly never received in a meaningful way. That is not a free pass. It is a reminder that these theories can pull against each other.

What the Court Thought the Board Allegedly Failed to Do

The court found it reasonably conceivable that Teligent’s directors failed to make the kind of good-faith effort Delaware law requires. The complaint alleged that the board had no committee charged with overseeing FDA compliance, even though the company operated in a heavily regulated pharmaceutical environment. Teligent’s audit committee allegedly focused on SEC compliance, not FDA compliance. The complaint also alleged that across years of committee meetings, there was no meaningful board-level structure aimed at core regulatory oversight.

It got worse. The alleged problems were not limited to committee design. The complaint described an absence of processes and protocols requiring management to keep the board informed about FDA compliance issues. It also alleged weak or inadequate training structures tied to those central compliance risks. In a line that will likely appear in presentations for the next several years, the court said the allegations described something “about as close to an utter failure as it gets.”

That phrase should make boards sit up straighter. The ruling did not say every pharmaceutical company must use the same committee format or reporting template. It said a board overseeing a regulated business cannot leave a mission-defining compliance area floating around without a real board-level home, without clear reporting channels, and without a documented process showing that the directors actually tried.

Why the Board-Level Red-Flags Claim Failed

Even though the complaint painted a rough picture of recurring FDA trouble, the court dismissed the directors’ red-flags claim. Why? Because the allegations suggested that management had broad discretion over what reached the board and how it was framed. That made it difficult to infer that the directors consciously ignored clearly presented warning signs.

This is a subtle but important point. The court was not saying the FDA issues were minor. It was saying the complaint better supported an inference that the board was insufficiently informed than an inference that the board had a clear view of the problem and deliberately looked away. In other words, the alleged problem was less “the board saw the flames and went to lunch” and more “the board never had a dependable smoke detector in the first place.”

That analytical distinction will matter in future cases. Plaintiffs cannot simply toss both theories into the complaint like extra toppings on a pizza and assume more is better. Teligent shows that courts will test whether the theories fit together logically.

What Happened to the Officers?

The officer claims are another reason Teligent is getting so much attention. Delaware has already made clear in recent years that officers, like directors, have fiduciary duties that include oversight obligations. But those duties are context-specific and tied to the officer’s area of responsibility.

In Teligent, the court allowed claims to proceed against former CEO Jason Grenfell-Gardner and former Chief Science Officer Stephen Richardson. The theory was not that they built the perfect regulatory machine and then accidentally misplaced it. It was that they plausibly knew about serious FDA-related issues and failed to report them upward to the board. In a governance chain, senior officers are not decorative middlemen. They are supposed to move critical risk information upstairs, not keep it trapped in the executive suite like a bad family secret.

By contrast, the court dismissed the claims against former CFO Damian Finio. That part of the opinion is a valuable reminder that officer oversight duties are not unlimited free-range obligations. The court reasoned that FDA compliance is not ordinarily understood as a financial-risk category merely because it has financial consequences. The plaintiff did not allege that Finio was the officer who should have escalated the FDA issues. Instead, the allegations centered on his failure to tell the board about costs associated with a separate matter. The court found that too disconnected from the compliance harm at issue.

The takeaway is practical: officers must oversee and escalate risks within their sphere of responsibility, and the board should be crystal clear about where those spheres begin and end. Ambiguity may look flexible during calm periods, but in litigation it often looks like neglect wearing business casual.

Why Teligent Could Influence Governance Beyond Pharma

Although Teligent arose in the pharmaceutical context, its lessons are not confined to drugmakers. Any business operating under intensive regulation should pay attention. Financial institutions, aerospace manufacturers, healthcare companies, food producers, data-driven businesses handling consumer privacy, and companies dependent on licenses or agency approvals all have their own version of “mission-critical” or central compliance risk.

Teligent also fits into a larger Delaware pattern shaped by cases such as Marchand, Clovis, Boeing, and McDonald’s. Together, these decisions tell a consistent story: courts will not second-guess every board after a crisis, but they will examine whether directors and officers actually built and used systems to monitor the company’s most important legal and operational risks. Teligent extends that story by showing how post-bankruptcy litigation and officer-level exposure can keep the pressure on long after the original corporate trauma.

Practical Lessons for Boards and Executives

1. Give Critical Risks a Board-Level Home

If a risk is central to the company’s ability to operate, someone at the board level must own oversight responsibility for it. That may be a full board function, a dedicated committee, or a carefully drafted charter assignment. What it cannot be is a shrug.

2. Build Reporting Protocols, Not Just Good Intentions

Management should know what must be escalated, when it must be escalated, how it must be documented, and to whom it goes. A reporting culture that depends on vibes is not a system.

3. Document Oversight in Meeting Materials and Minutes

Teligent is a cautionary tale about sparse documentation. If oversight happened, the company should be able to show it. Minutes do not need to read like a Russian novel, but they should reflect that directors addressed the right risks in the right forum.

4. Define Officer Responsibility Clearly

Officer liability is real, but it is role-based. Companies should map responsibilities, escalation duties, and cross-functional coordination with enough clarity that no one can later pretend the regulatory grenade belonged to another department.

5. Train the Organization Like It Matters, Because It Does

Training is not glamour work. No one throws a parade for updated compliance modules. But when training around central risks is weak or inconsistent, it becomes part of the story plaintiffs tell about bad-faith oversight.

Experience From the Trenches: What Situations Like Teligent Usually Feel Like Inside a Company

In practice, situations like Teligent rarely begin with a dramatic boardroom confession. They usually start with a series of seemingly manageable issues: a regulator asks follow-up questions, quality teams flag process gaps, consultants are hired to “help tighten things up,” and leadership tells itself the problems are serious but temporary. Nobody thinks they are starring in the opening scene of a future Delaware opinion.

Then the pattern sets in. Management presentations to the board become selective. Bad news gets softened with optimistic framing. Meeting agendas are crowded, so compliance updates get squeezed between earnings guidance and strategic initiatives. A committee may exist on paper, but its charter does not match the company’s real risk profile. Directors hear enough to know there is smoke, but not enough to understand where the fire is spreading.

Another common feature is fragmentation. Quality, legal, regulatory, finance, and operations each hold a different piece of the puzzle. Everyone is working hard, yet no one is responsible for assembling the full picture for the board. The result is not always intentional concealment. Sometimes it is a systems problem. Unfortunately, courts do not award participation trophies for chaotic good intentions.

By the time outside counsel or restructuring professionals arrive, the company often has binders full of remediation plans, consultant invoices, and action items. Those documents can create the appearance of motion, but they do not necessarily prove that the board had a functioning oversight system at the right time. A company may spend millions fixing a problem and still face the question that matters most in a Caremark case: where was the board-level architecture before the crisis became existential?

That is why governance veterans constantly return to boring-sounding basics. Clear committee mandates. Regular reporting schedules. Escalation triggers. Written summaries of regulatory events. Training that reaches the people doing the work. Minutes that show the board engaged with the right issues. None of that feels glamorous in the moment. All of it becomes priceless when someone later asks whether the directors and officers made a good-faith effort.

The real-world lesson from Teligent is not that companies need perfect foresight. It is that they need disciplined habits before trouble explodes. In a regulated business, oversight cannot be episodic, personality-driven, or hidden inside one executive’s inbox. It has to be designed, repeated, and visible. When that infrastructure exists, companies have a fighting chance to show they tried. When it does not, plaintiffs get to write the story for them.

Final Takeaway

The Teligent ruling is not a declaration that every regulatory failure will become a winning oversight case. Delaware still demands more than hindsight criticism and corporate hand-wringing. But the decision does make one thing unmistakably clear: when a company’s core business depends on regulatory compliance, directors and officers must be able to show a real, functioning, board-connected oversight system.

Teligent allegedly lacked that kind of structure, and the case survived because the complaint was specific, well-sourced, and unusually well informed. For boards, that is the real warning label. A weak oversight framework is risky enough in ordinary times. After a bankruptcy, with a company-controlled plaintiff holding the internal paper trail, it can become the center of the case.

Note: This article is for general informational and editorial purposes only and does not constitute legal advice.